An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101

G. A. Wittert; R. W. Harrison; M. J. Buckley; J. Wlodarczyk

doi:10.1111/andr.12129

An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101

Andrology ◽

10.1111/andr.12129 ◽

2016 ◽

Vol 4 (1) ◽

pp. 41-45 ◽

Cited By ~ 3

Author(s):

G. A. Wittert ◽

R. W. Harrison ◽

M. J. Buckley ◽

J. Wlodarczyk

Keyword(s):

Bioequivalence Study ◽

Crossover Design ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Testosterone Gel ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727214353.793527520 ◽

2017 ◽

Author(s):

John Amory

Keyword(s):

Bioequivalence Study ◽

Crossover Design ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Testosterone Gel ◽

Open Label Phase

Download Full-text

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00438-6 ◽

2016 ◽

Vol 17 (1) ◽

pp. 48-56 ◽

Cited By ~ 108

Author(s):

Michael L Wang ◽

Hun Lee ◽

Hubert Chuang ◽

Nicolaus Wagner-Bartak ◽

Frederick Hagemeister ◽

...

Keyword(s):

Mantle Cell Lymphoma ◽

Cell Lymphoma ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Phase 2 Trial ◽

Mantle Cell ◽

Open Label Phase

Download Full-text

Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan

EClinicalMedicine ◽

10.1016/j.eclinm.2021.101078 ◽

2021 ◽

pp. 101078

Author(s):

Kunsulu Zakarya ◽

Lespek Kutumbetov ◽

Mukhit Orynbayev ◽

Yergali Abduraimov ◽

Kulyaisan Sultankulova ◽

...

Keyword(s):

Clinical Trials ◽

Phase 1 ◽

Healthy Adults ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Open Label Phase ◽

Single Blind ◽

Phase 2 Clinical Trials

Download Full-text

Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(20)30027-9 ◽

2020 ◽

Vol 21 (4) ◽

pp. 561-570 ◽

Cited By ~ 3

Author(s):

Arthur J A T Braat ◽

Rutger C G Bruijnen ◽

Rob van Rooij ◽

Manon N G J A Braat ◽

Frank J Wessels ◽

...

Keyword(s):

Liver Metastases ◽

Neuroendocrine Tumour ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00581-x ◽

2021 ◽

Author(s):

Ashesh B Jani ◽

Eduard Schreibmann ◽

Subir Goyal ◽

Raghuveer Halkar ◽

Bruce Hershatter ◽

...

Keyword(s):

Prostate Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Conventional Imaging ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Pet Ct ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718028323.793480222 ◽

2013 ◽

Author(s):

Richard Riedel

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Metastatic Soft Tissue Sarcoma ◽

Previously Treated

Download Full-text

Faculty Opinions recommendation of PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725357238.793504256 ◽

2015 ◽

Author(s):

Michele Spina

Keyword(s):

Salvage Therapy ◽

Hodgkin’S Lymphoma ◽

Brentuximab Vedotin ◽

Hodgkin's Lymphoma ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726215272.793539632 ◽

2017 ◽

Author(s):

Patrick Nana-Sinkam

Keyword(s):

Lung Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Previously Treated ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.730774358.793564974 ◽

2019 ◽

Author(s):

Anna Rita Migliaccio

Keyword(s):

Myelodysplastic Syndromes ◽

Lower Risk ◽

Dose Finding ◽

Extension Study ◽

Phase 2 ◽

Open Label ◽

Finding Study ◽

Open Label Phase ◽

Dose Finding Study

Download Full-text

Faculty Opinions recommendation of Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736408717.793563871 ◽

2019 ◽

Cited By ~ 1

Author(s):

Sandra Nuyts ◽

Sarah Deschuymer

Keyword(s):

Squamous Cell Carcinoma ◽

Robotic Surgery ◽

Cell Carcinoma ◽

Neck Dissection ◽

Squamous Cell ◽

Randomised Trial ◽

Transoral Robotic Surgery ◽

Phase 2 ◽

Open Label ◽

Open Label Phase

Download Full-text